The S&P 500 contains leading companies, but not every constituent merits a buy rating. Three stocks in particular face structural challenges that make them unattractive at current valuations.
Freight rail operator CSX (NASDAQ:CSX) has stagnated. Sales have flatlined over the past two years, as have unit volumes. Operating margins have compressed by 4.4 percentage points over five years. At $51.85 per share, the stock trades at 22.8 times forward earnings—expensive for a company with no growth.
Thermo Fisher Scientific (NYSE:TMO) suffers from scale. Its 3.9 percent annualized sales growth over five years has lagged healthcare peers. Organic revenue has disappointed for two straight years. Earnings per share have gone nowhere over five years. The stock trades at $695.14, or 26.3 times forward earnings, pricing in growth the company is not delivering.
Travelers (NYSE:TRV) is held back by its size. Net premiums earned grew just 3.1 percent over two years, lagging other financial institutions. Management guides to 1.8 percent sales growth in the next 12 months—a slowdown from recent trends. Book value per share has grown only 4.1 percent annually over five years, well below peer performance. At $397.19, or 2.7 times forward book value, the stock offers no margin of safety for a company facing secular headwinds.
All three stocks share a common flaw: they trade at premium valuations despite offering below-peer growth. For investors, these are names to avoid.
